Sharfstein On Zohydro: FDA Should Require Opioid Abuse Deterrent Standards

Former FDA Principal Deputy Commissioner Joshua Sharfstein suggests FDA create a pathway for development of new products for simultaneous treatment of chronic pain and opioid disorder.